Global Pneumonia Therapeutics Market 2017-2021

  • ID: 4430332
  • Report
  • Region: Global
  • 87 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Bayer
  • Biotest
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • MORE
About Pneumonia Therapeutics

Pneumonia is a respiratory disease characterized by inflammation of air sacs in lungs due to bacterial or viral infection. Pneumonia therapeutics market encompasses drugs and vaccines used for the treatment of pneumonia along with oxygen therapy. The global pneumonia therapeutics market is an important part of the global respiratory disorder drugs market. The treatment of pneumonia involves three major categories, namely, vaccines, drugs, and oxygen therapy. Oxygen therapy is often used as a supplement to other therapies when the patient faces difficulty in breathing.

The analysts forecast the global pneumonia therapeutics market to grow at a CAGR of 6.66% during the period 2017-2021 .

Covered in this report

The report covers the present scenario and the growth prospects of the global pneumonia therapeutics market for 2017-2021 . To calculate the market size, the report considers the sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Pneumonia Therapeutics Market 2017-2021 , has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer
Other prominent vendors
  • AstraZeneca
  • Bayer
  • Biotest
  • Ono Pharmaceutical
  • Tetraphase Pharmaceuticals
Market drivers
  • Increased awareness about prophylaxis by vaccines
  • For a full, detailed list, view the full report
Market challenges
  • New strains of MDR bacteria
  • For a full, detailed list, view the full report
Market trends
  • Strong pipeline
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Bayer
  • Biotest
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: DISEASE OVERVIEW

PART 06: MARKET ECOSYSTEM
  • Market segmentation analysis
PART 07: MARKET SIZING
  • Market size and forecast 2016-2021
PART 08: PIPELINE ANALYSIS

PART 09: FIVE FORCES ANALYSIS

PART 10: MARKET SEGMENTATION BY PRODUCT TYPE
  • Segmentation by product type
  • Comparison by product type
  • Global pneumonia vaccines market
  • Global pneumonia anti-infectives market
  • Global pneumonia oxygen therapy market
  • Market opportunity by product type
PART 11: MARKET SEGMENTATION BY PNEUMONIA TYPE
  • CAP
  • HCAP
PART 12: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Pneumonia therapeutics market in Americas
  • Pneumonia therapeutics market in EMEA
  • Pneumonia therapeutics market in APAC
  • Market opportunity
PART 13: DECISION FRAMEWORK

PART 14: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 15: MARKET TRENDS
  • Strong pipeline
  • Rising global initiatives for pneumonia treatment
  • Rise in respiratory infection cases
PART 16: VENDOR LANDSCAPE

PART 17: VENDOR ANALYSIS
  • Vendor overview
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer
PART 18: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Global pneumonia therapeutics categories
Exhibit 02: Parent market of the global pneumonia therapeutics market
Exhibit 03: Global pneumonia therapeutics market segments
Exhibit 04: Global pneumonia therapeutics market 2016-2021 ($ millions)
Exhibit 05: Global pneumonia therapeutics market year-over-year (YoY) growth 2017-2021 (%)
Exhibit 06: Global pneumonia therapeutics pipeline landscape
Exhibit 07: Key clinical trials in the global pneumonia therapeutics market
Exhibit 08: Global pneumonia therapeutics market by product type 2016-2021 (%)
Exhibit 09: Global pneumonia therapeutics market comparison by product type
Exhibit 10: Global pneumonia vaccines market 2016-2021 ($ millions)
Exhibit 11: Global pneumonia vaccines market YoY growth 2017-2021 (%)
Exhibit 12: Global pneumonia anti-infectives market 2016-2021 ($ millions)
Exhibit 13: Global pneumonia anti-infectives market YoY growth 2017-2021 (%)
Exhibit 14: Global pneumonia oxygen therapy market 2016-2021 ($ millions)
Exhibit 15: Global pneumonia oxygen therapy market YoY growth 2017-2021 (%)
Exhibit 16: Market opportunity by product type
Exhibit 17: Global pneumonia therapeutics market by geography 2016-2021 (%)
Exhibit 18: Regional comparison
Exhibit 19: Pneumonia therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Pneumonia therapeutics market YoY growth in Americas 2017-2021 (%)
Exhibit 21: Pneumonia therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Pneumonia therapeutics market YoY growth in EMEA 2017-2021 (%)
Exhibit 23: Pneumonia therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Pneumonia therapeutics market YoY growth in APAC 2017-2021 (%)
Exhibit 25: Factors driving awareness toward prophylaxis treatment
Exhibit 26: Development of microbial resistance
Exhibit 27: Major global initiatives for pneumonia treatment
Exhibit 28: GlaxoSmithKline: Key highlights
Exhibit 29: GlaxoSmithKline: Strength assessment
Exhibit 30: GlaxoSmithKline: Strategy assessment
Exhibit 31: GlaxoSmithKline: Opportunity assessment
Exhibit 32: Merck Sharp & Dohme: Key highlights
Exhibit 33: Merck Sharp & Dohme: Strength assessment
Exhibit 34: Merck Sharp & Dohme: Strategy assessment
Exhibit 35: Merck Sharp & Dohme: Opportunity assessment
Exhibit 36: Novartis: Key highlights
Exhibit 37: Novartis: Strength assessment
Exhibit 38: Novartis: Strategy assessment
Exhibit 39: Novartis: Opportunity assessment
Exhibit 40: Pfizer: Key highlights
Exhibit 41: Pfizer: Strength assessment
Exhibit 42: Pfizer: Strategy assessment
Exhibit 43: Pfizer: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca
  • Bayer
  • Biotest
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • MORE
New Report Released: - Global Pneumonia Therapeutics Market 2017-2021

The author of the report recognizes the following companies as the key players in the global pneumonia therapeutics market: GlaxoSmithKline, Merck Sharp & Dohme, Novartis, and Pfizer.

Other Prominent Vendors in the market are: AstraZeneca, Bayer, Biotest, Ono Pharmaceutical, and Tetraphase Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is Strong pipeline.The pipeline molecules in the respiratory disorder drugs market are rising at a good pace as consistent funding opportunity for R&D are available, and it is expected to fuel the market growth during the forecast period. For example, one of the popular funding bodies, Bill & Melinda Gates Foundation is supporting a new vaccine development by providing financial aid to combat pneumococcal disease in neonates.”

According to the report, one of the major drivers for this market is Increased awareness about prophylaxis by vaccines. The awareness about prophylaxis has increased significantly in the past few years, and as a result, the world population is preferring to opt for preventive measures to reduce the possibility of disease onset. Preference to prevent pneumonia works as growth booster for the pneumonia vaccine market. Federal bodies also contribute significantly to awareness-raising campaigns. For instance, the National Institutes of Health (NIH) recommends regular pneumococcal vaccinations in its clinical guidelines for geriatric patients and patients at high risk for pneumonia. Such recommendations help population become aware of prophylaxis treatments thereby, driving the growth of the pneumonia therapeutics market.

Further, the report states that one of the major factors hindering the growth of this market is New strains of MDR bacteria. The global pneumonia therapeutics market includes antimicrobials as one of the key therapeutic regimens for the treatment of pneumonia. The rising bacterial resistance is a challenge because the available treatment options are losing their effectiveness. Usually, antimicrobials are prescribed for multiple diseases, which results in repetitive exposure of the microbe to the drug. This unnecessary exposure to antimicrobials can contribute to multi-drug resistance in bacteria. As per the CDC, antibiotics are not prescribed optimally in 50% of the cases, which implies that they are prescribed in the scenarios when they are not required. Incorrect dosing and duration of antibiotics also result in drug resistance. Transmission of resistant bacterial strains from one person to other and from non-human sources are also contributing to the development of new MDR bacterial strains.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Novartis
  • Pfizer
  • AstraZeneca
  • Bayer
  • Biotest
  • Ono Pharmaceutical
  • Tetraphase Pharmaceuticals
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll